The Cancer Treatment Center of America is a local network containing several hospitals which aid patients who are suffering from cancer. It uses certain approaches to treat sickness through surgery, radiation and chemotherapy. CTCA offers therapies that are used to assist the ill both physically and emotionally for their well-being.
The institution has been recognized due its great work and effort in treating cancer patients hence being ranked among the best facilities for cancer treatments in the country. However, CTCA has linked up with some firms to teach men on the prostate cancer since the majority are affected by it. It has also improved the entry for screenings so as people can participate in knowing their health.
CTCA has been creating alertness of the prostate cancer to general public and guiding them on the merits of having screenings early so as to avoid major illness in the future. It also hosts campaigns to educate people on the importance of the illness. The CTCA hospital in Chicago always hosts an event for the community and patients so as to offer them with guidance and treatments. At Tulsa, the CTCA health facilities also have an event for the local colleges and high school, creating awareness of the illness.
Cancer Treatment Center of America deals with advanced therapies so as to assist side effects like pain, nausea and fatigue from the patients. CTCA was formed by Richard j Stephenson after he lost his mother due to cancer.
He felt much was not done to treat his mother hence established the first CTCA facility in 1988. The CTCA hospitals are currently four nationally and they have complied with every regulation as per the law requires. Every institution consists of highly qualified doctors who are specialized with cancer treatments and use modernized technologies to treat cancer.
To Know More Click Here
Over the past few years, the general population has witnessed an increase in the number of cancer survivors. The surge is a result of the expansion of cancer services, screening efforts, and breakthrough cancer research. Furthermore, cancer treatments centers are now better equipped. A report from the Surveillance, Epidemiology and End Results program show remarkable statistics of the number of cancer survivors’ population. The results of the extensive research show an increase to over fifteen million in 2016. This is almost four times the number just three decades ago.
However, we would not be talking about such improvement without the helping hand of scientific research. The brains behind fighting cancer are overlooked while they toil to find a cure for this menace. One such character who is outstanding is Eric Lefkofsky. The co-founder of Tempus is spearheading the lead in developing the next generation technology to modernize cancer treatment. The health-startups help the physician to provide the right prescription for their cancer patients.
The 48-year old is the head of Tempus, the company battling cancer. He attributes his drive to fighting cancer to the experience of a close relative undergoing cancer treatment. He combines his efforts with several scientists in the field, while also collaborating with hospitals on advancements in cancer treatment. Through their state-of-the-art facilities, they help identify the genomic data of a patient providing their data science. The information is critical in picking the correct clinical care for the patient.
Additionally, Eric is an avid philanthropist towards cancer research and development. His foundation regularly donates to cancer research institutions and universities. This shows his actual goal of investing in tackling cancer on behalf of humanity. He argues that medical discoveries should be more critical, and advanced health infrastructure will be the key to precision medicine. As his efforts begin to bear fruit, Eric believes big data as a tool that is somewhat underutilized even though it will be one way of moving forward. With the number of cancer survivors increasing, understanding nature of cancer is a vital aspect in determining the success of the clinical trials.
To Learn More Click Here
Clay Siegall is one of the nation’s foremost pharmaceutical researchers. Specializing in the development of antibody drug conjugates, a type of drug that uses synthetic human antibodies to deliver a highly lethal cytotoxin directly to the site of malignant tumors, Dr. Siegall is responsible for the development of some of the most cutting-edge cancer treatments seen since the 1950s. After a career of more than 30 years of developing some of the most innovative cancer treatments in the world, Dr. Siegall now leads his own firm, Seattle Genetics, which is credited with the first ever FDA-approved antibody drug conjugate, ADCetris, for the treatment of refractory non-Hodgkin’s lymphoma.
Dr. Clay Siegall first became interested in cancer research while still attending college. A family member became ill with the disease while Dr. Siegall was still in undergraduate school. At one point, the family member developed severe anemia, nearly leading to their death. This is what made Dr. Siegall realize that there must be a better way to treat cancer than to use drugs that oftentimes have death as a side effect. The brutality and crudeness of standard chemotherapeutics regimens left Dr. Siegall certain that there must be another way to treat this terrible disease.
After receiving a PhD in genetics from George Washington University, Dr. Siegall was hired on by the National Cancer Institute, one of the most prominent cancer research organizations in the world. He worked there for four years, working on an exciting new class of drugs known as targeted cancer therapies. After spending time learning the trade at the National Cancer Institute, Dr. Siegall was hired by Bristol-Myers Squibb, one of the leading private pharmaceutical companies in the world.
While at Bristol-Myers Squibb, Dr. Siegall rose to the rank of senior researcher, leading a team of his own scientists that he exclusively dedicated to the research and development of new types of targeted cancer therapy. It was during this time that Dr. Siegall became aware of the possibility of using human antibodies to deliver a highly lethal cytotoxin directly to the site of a malignant tumor. He eventually synthesized prototypical drugs of this type, calling them antibody drug conjugates.
Dr. Siegall immediately realized the enormous commercial potential for this new line of drugs. He eventually left Bristol-Myers Squibb and started his own biotech firm, Seattle Genetics. Seattle Genetics would be exclusively dedicated to the research and development of antibody drug conjugates, focusing on cancer types that had not seen significant mortality improvements in decades.
Today, Seattle Genetics is the only company to have received FDA approval for an antibody drug conjugate. It continues saving thousands of lives each year.